For Thousands with HIV, This State's Drug Coverage Cuts Could Be Life or Death

Why It Matters

The cuts jeopardize viral suppression for thousands, risking higher healthcare costs and a public‑health setback that extends beyond individual patients.

Key Takeaways

• Florida cuts HIV drug eligibility from 400% to 130% FPL.
• Up to 16,000 Floridians risk losing free antiretroviral coverage.
• Monthly cost of Biktarvy can reach $5,000‑$6,000 without aid.
• Legal challenges filed; bipartisan lawmakers consider restoring eligibility.
• Potential loss of treatment could increase hospitalizations and public‑health costs.

Summary

Florida’s health department announced sweeping cuts to its HIV drug assistance program, slashing income eligibility from 400 % of the federal poverty level to 130 % and setting an end‑date of March 31, 2026 for current beneficiaries. The move targets the state’s projected $120 million budget shortfall but threatens to strip thousands of patients of free antiretroviral therapy.

The policy could affect as many as 16,000 Floridians living with HIV. Without state coverage, a 30‑day supply of Biktarvy—one of the most prescribed regimens—costs $5,000‑$6,000, a price most patients cannot afford. Emergency rules have already taken effect, leaving many in limbo while lawmakers debate a short‑term funding fix.

Activists like Tori Samuel, diagnosed at 19 and now a vocal advocate, warn that loss of medication would jeopardize viral suppression and force patients into costly emergency care. The AIDS Healthcare Foundation has filed multiple lawsuits, and a bipartisan coalition in Tallahassee is pushing a restoration bill pending the governor’s signature.

If the cuts stand, public‑health officials anticipate a surge in hospitalizations, higher transmission risk, and broader fiscal strain from untreated HIV cases. The controversy underscores how budgetary decisions can directly impact health outcomes and highlights the political leverage of advocacy groups in shaping state policy.

Original Description

Florida is cutting access to HIV medication through its AIDS Drug Assistance Program (ADAP), putting up to 16,000 people at risk of losing life-saving treatment.

For Tori Samuel, these medications have kept her alive, her husband HIV-negative, and her children born HIV-free. A 30-day supply of the drugs she relies on can cost up to $6,000 — far out of reach without coverage.

State officials say the changes are due to rising costs. Patients and advocates warn they could reverse decades of progress in the fight against HIV.

00:00 What’s at stake

00:52 Meet Tori Samuel

02:13 Fighting back at the Florida Capitol

05:47 Policy changes take effect

06:23 An uncertain future for patients

Subscribe to The Washington Post on YouTube: https://wapo.st/2QOdcqK